Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
HIV Infections
Interventions
DRUG

stavudine extended-release, lamivudine, efavirenz

Trial Locations (47)

Unknown

Local Institution, Hobson City

Local Institution, Montgomery

Local Institution, Phoenix

Local Institution, Little Rock

Local Institution, Los Angeles

Local Institution, Sacramento

Local Institution, San Mateo

Local Institution, Torrance

Local Institution, Denver

Local Institution, Norwalk

Local Institution, Stratford

Local Institution, Washington D.C.

Local Institution, Fort Lauderdale

Local Institution, Miami

Local Institution, Miami Beach

Local Institution, Pensacola

Local Institution, Tampa

Local Institution, Decatur

Local Institution, Chicago

Local Institution, Indianapolis

Local Institution, New Orleans

Local Institution, Baltimore

Local Institution, Boston

Local Institution, Berkley

Local Institution, Detroit

Local Institution, St Louis

Local Institution, Las Vegas

Local Institution, Hackensack

Local Institution, Jersey City

Local Institution, Neptune City

Local Institution, Somers Point

Local Institution, Manhasset

Local Institution, New York

Local Institution, The Bronx

Local Institution, Charlotte

Local Institution, Huntersville

Local Institution, Washington

Local Institution, Winston-Salem

Local Institution, Philadelphia

Local Institution, Reading

Local Institution, Dallas

Local Institution, Galveston

Local Institution, Houston

Local Institution, Annandale

Local Institution, Hampton

Local Institution, Seattle

Local Institution, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY